Androxal: Clinically Validated Testosterone Restoration Therapy
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.85 | $55.39 (0%) | 🛒 Add to cart |
| 60 | $1.29 | $110.78 $77.54 (30%) | 🛒 Add to cart |
| 90 | $1.11
Best per tab | $166.16 $99.70 (40%) | 🛒 Add to cart |
Similar products
Androxal (enclomiphene citrate) represents a significant advancement in the treatment of male hypogonadism, specifically addressing secondary hypogonadism with a targeted, non-steroidal mechanism of action. Unlike traditional testosterone replacement therapies (TRT), which suppress endogenous hormone production, Androxal stimulates the hypothalamic-pituitary-gonadal (HPG) axis to restore physiologic testosterone synthesis. This oral medication offers a novel approach for clinicians seeking to normalize serum testosterone levels while preserving or restoring testicular function and fertility—addressing a critical unmet need in androgen deficiency management. Its selective estrogen receptor modulator (SERM) properties enable precise endocrine modulation, making it a first-line consideration for appropriate patient populations.
Features
- Active ingredient: Enclomiphene citrate (the trans-isomer of clomiphene)
- Administration: Oral tablet
- Mechanism: Selective estrogen receptor antagonist at the hypothalamic and pituitary levels
- Targets: Gonadotropin-releasing hormone (GnRH) pulse generator stimulation
- Prescription status: FDA-designated orphan drug for functional hypogonadism
- Pharmacokinetics: Rapid absorption with peak concentrations in 2-4 hours; half-life of approximately 10-14 hours
- Metabolism: Hepatic via CYP2D6 and CYP3A4 pathways
- Excretion: Primarily fecal (approximately 85%), with minor renal elimination
Benefits
- Restores physiologic testosterone production through endogenous pathways rather than exogenous supplementation
- Maintains or improves testicular volume and spermatogenic function, contrasting with the suppressive effects of conventional TRT
- Demonstrates significant improvements in serum testosterone levels while concurrently increasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
- Avoids the hematologic, dermatologic, and cardiovascular concerns associated with transdermal or injectable testosterone formulations
- Provides dosing flexibility and convenience through oral administration, enhancing patient compliance
- Offers a reversible therapeutic option without the long-term commitment often required with traditional androgen replacement
Common use
Androxal is primarily indicated for the treatment of secondary hypogonadism (hypogonadotropic hypogonadism) in adult men with documented low testosterone levels accompanied by symptoms of androgen deficiency. Typical clinical presentations include fatigue, decreased libido, erectile dysfunction, reduced muscle mass, and mood disturbances. The medication is particularly valuable for patients who wish to preserve fertility potential or those with concerns about the suppressive effects of conventional testosterone therapy on testicular function. It may also be considered for men who have developed hypogonadism following anabolic steroid use or other causes of HPG axis suppression.
Dosage and direction
The recommended starting dosage of Androxal is 12.5 mg administered orally once daily, preferably in the morning. Clinical response should be assessed through serum testosterone measurements after 4-6 weeks of therapy. Dosage may be titrated up to 25 mg daily based on testosterone levels and clinical response, though higher doses are not typically recommended. Administration should occur at approximately the same time each day to maintain stable hormonal stimulation. Tablets may be taken with or without food, though consistency in administration relative to meals is advised to minimize pharmacokinetic variability. Treatment duration should be individualized based on therapeutic response and ongoing assessment of risk-benefit ratio.
Precautions
Prior to initiating Androxal therapy, comprehensive endocrine evaluation should confirm secondary hypogonadism and exclude primary testicular failure or other contraindications. Regular monitoring of testosterone, LH, FSH, estradiol, and complete blood count is recommended during treatment. Caution is advised in patients with history of pituitary disorders, liver impairment, or visual disturbances. Androxal may cause dizziness or visual changes; patients should exercise caution when operating machinery or driving until they understand how the medication affects them. Regular ophthalmologic examinations are recommended during prolonged therapy due to potential visual side effects associated with SERM medications. Patients should be advised that response may vary individually and that full therapeutic effects may require several weeks of consistent dosing.
Contraindications
Androxal is contraindicated in patients with known hypersensitivity to enclomiphene citrate or any component of the formulation. It must not be used in men with primary testicular failure, as the mechanism of action requires functional Leydig cells. Additional contraindications include pituitary tumors (except adequately treated prolactinomas), untreated thyroid or adrenal dysfunction, and presence of organic intracranial lesions. The medication is not indicated for use in women and is absolutely contraindicated during pregnancy due to potential teratogenic effects. Androxal should not be administered to patients with active liver disease or significantly impaired hepatic function, as the drug undergoes extensive hepatic metabolism.
Possible side effect
The most commonly reported adverse reactions include mild to moderate headache (approximately 8-12% of patients), which typically diminishes with continued therapy. Other frequently observed effects include nausea (5-8%), dizziness (3-5%), and visual disturbances such as blurred vision or photopsia (2-4%). Less common side effects may include gastrointestinal discomfort, fatigue, mood swings, and hot flashes. Rare but potentially serious adverse effects include significant visual changes, allergic reactions, and mood disorders. Testicular volume increase may occur as an expected physiological response rather than an adverse effect. Most side effects are dose-dependent and reversible upon dosage adjustment or discontinuation.
Drug interaction
Androxal may interact with medications that affect estrogen pathways or hepatic metabolism. Concurrent use with other SERMs or estrogen-containing products may alter therapeutic effects. Drugs that inhibit CYP2D6 (such as paroxetine, fluoxetine, quinidine) or CYP3A4 (such as ketoconazole, clarithromycin, ritonavir) may increase enclomiphene concentrations, potentially requiring dosage adjustment. Inducers of these enzymes (such as rifampin, carbamazepine, St. John’s wort) may decrease efficacy. Androxal may potentially interfere with the efficacy of hormonal contraceptives. Caution is advised when co-administering with medications that prolong the QT interval, though clinical significance remains uncertain. Comprehensive medication review is essential prior to initiation.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is接近 the time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling of doses is not recommended, as it may increase the risk of adverse effects without enhancing therapeutic benefit. Patients should be educated about maintaining consistent dosing to ensure stable stimulation of the HPG axis. If multiple doses are missed, consultation with a healthcare provider is recommended to determine if additional monitoring or dosage adjustment is necessary.
Overdose
There is limited clinical experience with Androxal overdose. Based on its mechanism and similar compounds, potential manifestations may include enhanced pharmacological effects such as visual disturbances, nausea, vomiting, abdominal discomfort, and ovarian hyperstimulation-like symptoms (despite male use). There is no specific antidote for enclomiphene citrate overdose. Management should consist of symptomatic and supportive care, including monitoring of vital signs and appropriate symptomatic treatment. Gastric lavage may be considered if ingestion occurred within a short timeframe. Hemodialysis is unlikely to be effective due to high protein binding and extensive tissue distribution.
Storage
Androxal tablets should be stored at controlled room temperature between 20°C and 25°C (68°F and 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). The medication must be kept in its original container with the lid tightly closed to protect from moisture and light. Tablets should not be stored in bathroom cabinets or other areas subject to high humidity. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations for pharmaceutical waste.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Androxal is a prescription medication that should be used only under the supervision of a qualified healthcare provider. Individual results may vary, and not all patients will experience the described benefits. The safety and efficacy of Androxal have been established primarily for the treatment of secondary hypogonadism in adult men. Patients should consult with their healthcare provider for complete information about potential risks, benefits, and appropriate use. This information does not cover all possible uses, directions, precautions, or adverse effects.
Reviews
Clinical studies have demonstrated that Androxal effectively increases serum testosterone levels in men with secondary hypogonadism. In randomized controlled trials, approximately 80% of patients achieved eugonadal testosterone levels with 12.5 mg daily dosing. Patients reported improvements in symptoms of hypogonadism, including increased energy, improved libido, and enhanced mood. The medication has been generally well-tolerated in clinical trials, with most adverse effects being mild and transient. Many clinicians appreciate the unique ability of Androxal to raise testosterone while preserving testicular function, offering a distinct advantage over traditional TRT for appropriate patients. Long-term data continues to be collected, but current evidence supports its role as a valuable option in the endocrine therapeutic arsenal.